Patent ID: 7863284

Claim:
A method for aiding regression and palliation of ovarian cancer in a patient in need of such treatment which comprises administering to said patient an effective amount of a cyclopenta[g]quinazoline of the formula (I) wherein: A is a group OR 0 or NR 0 R 1 wherein R 0 and R 1 are each independently hydrogen or C 1-4 alkyl; p is an integer in the range 1 to 4; R 2 is ethyl, propyl, prop-2-enyl, prop-2-ynyl, 2-hydroxyethyl, 2-fluoroethyl, 2-bromoethyl or 2-cyanoethyl; Ar 1 is 1,4-phenylene which may optionally bear one or two substituents selected from the group consisting of chloro and fluoro; or Ar 1 is thiophene-2,5-diyl, thiazole-2,5-diyl; or pyridine-2,5-diyl; R 3 is a group of the formula: -A 5 -CON(R)CH(Y 4 )Y 5 in which A 5 is a C 1-6 alkylene group and R is hydrogen, C 1-4 alkyl, C 3-4 alkenyl or C 3-4 alkynyl; Y 4 is carboxy, tetrazol-5-yl, Nâ€”(C 1-4 alkylsulfonyl)carbamoyl, N-(phenyl-sulfonyl)carbamoyl which may optionally bear one or two substituents on the phenyl ring selected from the group consisting of halogeno, nitro, C 1-4 alkyl and C 1-4 alkoxy, tetrazol-5-ylthio, tetrazol-5-ylsulfinyl or tetrazol-5-ylsulfonyl; and Y 5 is a group of the formula -A 4 -CO 2 H in which A 4 is a C 2-6 alkylene group; the compound (I) optionally being in the form of a pharmaceutically acceptable salt or ester.